Literature DB >> 21413766

Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.

Sara Ståhl1, Rui Mm Branca, Ghazal Efazat, Maria Ruzzene, Boris Zhivotovsky, Rolf Lewensohn, Kristina Viktorsson, Janne Lehtiö.   

Abstract

The ephrin and Eph signaling circuit has been reported as deregulated in a number of tumor types including nonsmall cell lung cancer (NSCLC). Here we show that suppression of the ephrin-familly member ephrin B3 decreases NSCLC cell proliferation and has profound effects on cell morphology. To reveal which signaling networks ephrin B3 utilize to regulate such effects on growth and morphology, differential regulation of phosphorylated proteins was analyzed in the NSCLC cell line U-1810. Using strong cat ion exchange (SCX) and TiO(2)-based fractionation followed by nano-LC and mass spectrometry analysis, we identified 1083 unique phosphorylated proteins. Out of these, 150 proteins were found only when ephrin B3 is expressed, whereas 66 proteins were found exclusively in U-1810 cells with silenced ephrin B3. Network analysis of changes in the phosphoproteome with regard to the presence or absence of ephrin B3 expression generated a hypothesis that the site specific phosphorylation on Ser-897 detected on the erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is critical for the survival of NSCLC cells. Upstream of the EphA2 phosphorylation, activation of Akt1 on Ser 129 was also revealed as part of the ephrin B3-mediated signaling pathway. Phosphorylation of these sites was further confirmed by immune-based strategies in combination with mass spectrometry. Moreover, by further stepwise pathway walking, annotating the phosphorylated sites and their corresponding kinases upstream, our data support the process in which a Heat shock protein 90 isoform (HSP90AA1) acts as a protector of EphA2, thereby saving it from degradation. In addition, protein kinase CK2 (CK2) is suggested as a dominant kinase, activating downstream substrates to generate the effects on NSCLC proliferation and morphology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21413766     DOI: 10.1021/pr200037u

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  13 in total

Review 1.  Eph receptor signaling and ephrins.

Authors:  Erika M Lisabeth; Giulia Falivelli; Elena B Pasquale
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

2.  Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Authors:  Pierre Saintigny; Shaohua Peng; Li Zhang; Banibrata Sen; Ignacio I Wistuba; Scott M Lippman; Luc Girard; John D Minna; John V Heymach; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2012-07-17       Impact factor: 6.261

Review 3.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

Review 4.  Eph/ephrin signaling: genetic, phosphoproteomic, and transcriptomic approaches.

Authors:  Jeffrey O Bush; Philippe Soriano
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

5.  EphA2 and ephrin-A5 are not a receptor-ligand pair in the ocular lens.

Authors:  Catherine Cheng; Velia M Fowler; Xiaohua Gong
Journal:  Exp Eye Res       Date:  2017-06-23       Impact factor: 3.467

6.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

7.  Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Authors:  Alireza Azimi; Rainer Tuominen; Fernanda Costa Svedman; Stefano Caramuta; Maria Pernemalm; Marianne Frostvik Stolt; Lena Kanter; Pedram Kharaziha; Janne Lehtiö; Carolina Hertzman Johansson; Veronica Höiom; Johan Hansson; Suzanne Egyhazi Brage
Journal:  Cell Death Dis       Date:  2017-08-31       Impact factor: 8.469

8.  Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.

Authors:  S Ståhl; V O Kaminskyy; G Efazat; A Hyrslova Vaculova; S Rodriguez-Nieto; A Moshfegh; R Lewensohn; K Viktorsson; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2013-01-10       Impact factor: 8.469

9.  Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.

Authors:  Giulia Falivelli; Erika Mathes Lisabeth; Elena Rubio de la Torre; Gizeh Perez-Tenorio; Giovanna Tosato; Ombretta Salvucci; Elena B Pasquale
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

Review 10.  Systems biology approaches to develop innovative strategies for lung cancer therapy.

Authors:  K Viktorsson; R Lewensohn; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.